Aksamon nyxes: instructions for use
Aksamon in injections refers to cholinesterase inhibitors and is used for subcutaneous and intramuscular administration in the treatment of diseases of the nervous system.
The solution of aksamon is a colorless liquid with the active substance - ipidacrine hydrochloride monohydrate. As auxiliary substances, the dosage form contains water for injection and a solution of hydrochloric acid (0.1 M). In the pharmacy range is represented by two concentrations: 5 mg / ml and 15 mg / ml.
Pharmacological properties and indications for use
The chemical composition of the preparation and certain auxiliary substances endow it with appropriate pharmacological properties:
- Stimulation of nerve impulses;
- Improved conduction, disturbed by inflammatory processes and caused by prolonged use of potassium chloride, some antibacterial drugs and local anesthetics, injuries and other factors;
- The inhibition of dementia, characterized by the degradation of thinking, behavior and memory, and improving memory.
Indications for the use of the drug are diseases of the central and peripheral nervous system (paresis, paralysis, polyneuropathy, myasthenia, etc.), intestinal atony and rehabilitation of the patient with organic lesions of the central nervous system and motor disorders.
Aksamon in pricks can not be prescribed to children under 18 years of age, as there is no systematic data on clinical studies in this group. Other contraindications are:
- Various forms of epilepsy;
- Acute stage of peptic ulcer of stomach and duodenum;
- Disorders of the vestibular apparatus;
- Severe angina and bradycardia;
- Intestinal obstruction;
- Hypersensitivity to ipidakrinu.
Caution should be observed with thyrotoxicosis, acute diseases of the urinary and respiratory systems.
Pregnant Aksamon in pricks is also contraindicated, as it can cause premature birth, increasing the tone of the uterus. Data on the use of the drug during lactation are not available.
The route of administration (subcutaneously or intramuscularly) and the dosage of the prescribed drug depends on the disease and the features of its course.
- Treatment of diseases of the central nervous system
- In paresis and bulbar paralysis, the drug is administered twice a day intramuscularly or subcutaneously for 10-15 days, with dosage ranging from 5 to 15 mg. After the injection course, the use of a tablet form of the drug is possible.
- When rehabilitating patients with impaired motor activity and organic CNS lesions, the following scheme is used: 1-2 times a day Axamon is administered intramuscularly at a dosage of 10-15 mg for 15 days, and then the patient takes it in tablets.
- Treatment of peripheral UA diseases
- With myasthenia gravis and Aksamon syndrome is administered 1-3 times a day at a dosage of 15-30 mg, and then is given in tablet form. The course of treatment is up to 2 months.
- With polyradiculopathy and neuropathy, provoked by various factors, the drug is administered intramuscularly or subcutaneously for 10 days in a dosage of 5-15 mg. In day 1-2 injections. In severe forms of the disease course is up to 30 days with the transition to Axamon in tablets.
- When intestinal atony, the initial dose is 10-15 mg and is administered twice a day for 1-2 weeks.
The solution of the aksamon is well tolerated and does not adversely affect the fetus, the liver and the immune and endocrine systems.
In some cases, the following undesirable effects may develop:
- Violations of the nervous system and psyche - headache, tremor, cramps , dizziness and drowsiness;
- Narrowing of the pupil;
- Bradycardia (slow heartbeat) and chest pain;
- Nausea and increased salivation, possible vomiting, abdominal pain and diarrhea;
- Jaundice, rash and itching;
- General weakness, increased sweating.
When an itchy rash occurs, the doctor cancels the drug. With other side effects, either short-term use of the drug or the dosage is reduced.
If side effects occur that are not listed in the instructions, immediately consult a doctor.
When using the combination of Axamon and drugs that depress the central nervous system (tranquilizers, antipsychotics, antidepressants, hypnotics, sedatives and antimanic drugs), the sedative effect increases.
Strengthening the action of Axamon and the development of side effects occurs with the use of m-cholinomimetics (Pilocarpine, Acekledin), other inhibitors of cholinesterase and alcohol.
Combination with cholinergic drugs in the treatment of myasthenia increases the risk of developing a cholinergic crisis. And early use of β-blockers can lead to bradycardia.
When administered with local anesthetics, potassium chloride and aminoglycosides, weakening of the inhibitory effect on transmission and conduction of a pulse along nerve fibers is observed.
Simultaneous appointment with nootropics is acceptable.
In case of an overdose, the onset of side effects is provoked and the following symptoms are observed: bronchospasm, lacrimation, icterus of the skin, decreased blood pressure and bradycardia, convulsions, broken speech, anxiety and fear, drowsiness and weakness, narrowing of the pupils and uncontrolled urination and defecation.
Treatment involves the use of symptomatic drugs and m-holinoblokatorov (Cyclodol, Atropine).
Driving while using the drug
In the treatment of axamon, the patient should refrain from the following activities: requiring increased concentration of attention and rapid psychomotor reactions, driving and other mechanisms.
The storage location must be protected from light and out of the reach of children. The optimum temperature is up to 25 ° C.
Structural analogues of Aksamon according to the active substance: Amiridin, Neuromidin.
Price for Axamon in ampoules
Axamon solution for intramuscular and subcutaneous injection 15 mg / ml, 10 pcs. - from 1000 rubles.